3627-62-1

Basic information

• Product Name: 1-methyl-4-phenylpiperidine-4-carbonitrile
• Synonyms: 1-methyl-4-phenylpiperidine-4-carbonitrile;4-CYANO-1-METHYL-4-PHENYLPIPERIDINE;3-Methyl-4-phenyl-4-piperidinenitrile;1-Methyl-4-phenyl-4-piperidinecarbonitrile
• CAS NO: 3627-62-1
• Molecular Formula: C₁₃H₁₆N₂
• Molecular Weight: 200.27954
• EINECS: 222-847-7
• Mol File: 3627-62-1.mol

Chemical Properties

• Boiling Point: 332.5 °C at 760 mmHg
• Flash Point: 141 °C
• Appearance: /
• Density: 1.07 g/cm³
• Vapor Pressure: 0.000145mmHg at 25°C
• Refractive Index: 1.565
• CAS DataBase Reference: 1-methyl-4-phenylpiperidine-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 1-methyl-4-phenylpiperidine-4-carbonitrile(3627-62-1)
• EPA Substance Registry System: 1-methyl-4-phenylpiperidine-4-carbonitrile(3627-62-1)

Safety Data

• Hazardous Substances Data: 3627-62-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H16N2/c1-15-9-7-13(11-14,8-10-15)12-5-3-2-4-6-12/h2-6H,7-10H2,1H3

Upstream product

• 140-29-4 phenylacetonitrile 
• 51-75-2 nitrogen mustard 
• 55-86-7 mechlorethamine hydrochloride 
• 71258-18-9 1-benzyl-4-phenyl-piperidine-4-carbonitrile; hydrochloride 
• 50-00-0 formaldehyd 
• 40481-13-8 4-phenyl-4-cyanopiperidine 
• 149-73-5 trimethyl orthoformate 
• 74-88-4 methyl iodide 
• 854629-88-2 4-ethoxymethoxy-2-(2-ethoxymethoxy-ethyl)-2-phenyl-butyronitrile 
• 70179-05-4 2-phenyl-4-vinyloxy-2-(2-vinyloxy-ethyl)-butyronitrile 
• 50599-78-5 4-dimethylamino-2-phenyl-butyronitrile 
• 10469-27-9 α,α-bis(2-hydroxyethyl)phenylacetonitrile 
• 100119-73-1 1,5-dichloro-3-cyano-3-phenylpentane 
• 74-89-5 methylamine 

Downstream Products

• 7475-63-0 1-(1-methyl-4-phenylpiperidin-4-yl)propan-1-one 
• 774-52-7 1-methyl-4-phenylpiperidine 
• 1859-37-6 C-(1-methyl-4-phenyl-piperidin-4-yl)-methylamine 
• 96074-20-3 (1-methyl-4-phenyl-[4]piperidylmethyl)-(1-methyl-4-phenyl-[4]piperidylmethylen)-amine 
• 3627-48-3 pethidinic acid 
• 57-42-1 pethidine 
• 109161-93-5 1-methyl-4-phenyl-4-(1⁽²⁾H-tetrazol-5-yl)-piperidine 
• 96004-85-2 bis-(1-methyl-4-phenyl-[4]piperidylmethyl)-amine 
• 36887-11-3 1-methyl-4-acetyl-4-phenylpiperidine 
• 4220-10-4 (1-methyl-4-phenyl-piperidin-4-yl)-methanol 

Relevant articles and documents

Duraglutin artificial antigen and preparation method thereof

The invention provides a duramine artificial antigen and a preparation method thereof. The nitrile group of the 4-phenylpiperidine-4-carbonitrile is ingeniously reduced into the amino group; carboxylgroups capable of being used for crosslinking are introduced, so the characteristic original appearance of a duraglutin main ring is maintained; butanedioic anhydride is introduced, so acetyl functional groups on a duraglutin side chain is maintained on the said chain; the hapten synthesized by the process can maintain the characteristic group original appearance of duraglutin, and the synthesizedcorresponding artificial antigen has good specificity. The preparation process is simple, and the raw material source is not limited; the prepared artificial antigen can be used for animal immunization to obtain a corresponding duraglutin antibody, has strong antibody specificity, can be used in immunoassay, is suitable for research of various duraglutin immunoassay methods, and can be used as akey raw material for production of a duraglutin immunochromatographic kit.

Muscarinic acetylcholine receptor binding affinities of pethidine analogs

A series of pethidine analogs were synthesized and their affinities for the [3H]N-methyl-scopolamine (NMS) binding site on muscarinic acetylcholine receptors (mAChRs) were determined using M1, M3 or M5 human mAChRs expressed by Chinese hamster ovary (CHO) cell membranes. Compound 6b showed the highest binding affinities at M1, M3 and M5 mAChRs (Ki = 0.67, 0.37, and 0.38 μM, respectively).

HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF

The present invention relates to compounds of general formula (I) and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, and the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.

PHENYLPIPERIDINE MODULATORS OF MU-OPIOID RECEPTOR

The present invention relates to new phenylpiperidine modulators of μ-opioid receptors, pharmaceutical compositions thereof, and methods of use thereof.

THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS

The invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's disease

Nitrile analogs of meperidine as high affinity and selective sigma-1 receptor ligands

A series of N-substituted-4-cyano-4-phenylpiperidine analogs were synthesized and evaluated for binding affinity at opioid receptors and showed no affinity. The series similarity to previously reported σ ligands prompted analysis at σ receptors to determine the SAR for affinity at σ receptors. Within the N-substituent series the saturated analogs showed increased affinity at both σ receptors. Optimal chain length in the N-arylalkyl series for σ1 and σ2 receptors proved to be N-propylphenyl; extension to a four carbon chain dramatically decreased affinity at both receptors. Substituents in the 4-position affect only σ1 affinity; no change in affinity at σ2 was shown. The N-isobutyl, N-phenylpropyl, and N-benzyl analogs are worth pursuing due to their good affinity and selectivity at the σ1 receptor, whereas the N-benzyl analog exhibits the greatest selectivity for σ1.

Opioids and efflux transporters. Part 3: P-glycoprotein substrate activity of 3-hydroxyl addition to meperidine analogs

Numerous studies have shown that many clinically employed opioid analgesics are substrates for P-glycoprotein (P-gp), suggesting that up-regulation of P-gp may contribute to the development of central tolerance to opioids. The studies herein focus on the development of SAR for P-gp substrate activity in the meperidine series of opioids. Addition of a 3-OH to meperidine and the ketone analog of meperidine yielding bemidone and ketobemidone, respectively, significantly increased P-gp substrate affinity. The results of this study have implications in the development of novel analgesics to be utilized as tools to study the contribution of P-gp on the development of central tolerance to opioids.

Opioids and efflux transporters. Part 1: P-Glycoprotein substrate activity of N-substituted analogs of meperidine

P-Glycoprotein (P-gp) is an efflux transporter which is up-regulated at the blood-brain barrier in both morphine- and oxycodone-tolerant rats. Numerous studies have shown that many clinically employed opioid analgesics are substrates for P-gp, suggesting that up-regulation of P-gp may contribute to the development of central tolerance to opioids. The studies herein focus on the development of SAR for P-gp substrate activity in the meperidine series of compounds, and show that a meperidine analog of greater potency, N-phenylbutyl-N-normeperidine, has low activity as a P-gp substrate and has the potential to be utilized as a tool to study the contribution of P-gp to the development of central tolerance to opioids.

HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type or T-type calcium channel activity are disclosed. Specifically, a series of heterocyclic amides are disclosed of the general formula (I) where Z is N or CHNR2 and X is NR2, O, S, S=O or SO2. Among other definitions for R, R1, W and Y, the compounds of formula (1) are further characterized by at least one of W or Y being CR3Ar2 where Ar is an aromatic or heteroaromatic ring (for example, where W or Y is a benzhydryl moiety).

Urea derivatives as calcium channel blockers

Urea derivatives which comprise piperidine or piperazine rings and further substitution are effective in ameliorating conditions characterized by unwanted calcium ion channel activity.